methyl 2-(1-butyl-1H-indol-3-yl)-2-oxoacetate | 1443138-43-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: methyl 2-(1-butyl-1H-indol-3-yl)-2-oxoacetate
• 英文别名: Methyl 2-(1-butylindol-3-yl)-2-oxoacetate
• CAS: 1443138-43-9
• 化学式: C₁₅H₁₇NO₃
• 分子量: 259.305
• InChiKey: VCTGQOSGLHVDDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  48.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(1-butyl-1H-indol-3-yl)-2-oxoacetate 、 2-(1,2-苯并恶唑-3-基)乙酰胺 在 potassium tert-butylate 、 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.5h， 以35.2%的产率得到3-(benzo[d]isoxazol-3-yl)-4-(1-butyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 3-Benzisoxazolyl-4-indolylmaleimides as Potent, Selective Inhibitors of Glycogen Synthase Kinase-3β

  摘要：

  一系列新型的3-苯并异恶唑基-4-吲哚基-马来酰亚胺被合成并评估了它们对GSK-3β的抑制活性。大多数化合物表现出对GSK-3β的高抑制效力。其中，化合物7j以其0.73 nM的IC50值成为最有潜力的GSK-3β抑制剂。初步的结构-活性关系研究表明，吲哚环上及N1位上的不同取代基对GSK-3β抑制活性有不同程度的影响。化合物7c、7f、7j–l以及7o–q能在基于细胞的功能性检测中明显降低由Aβ诱导的Tau蛋白质过度磷酸化，这是通过抑制GSK-3β实现的。

  DOI：

  10.3390/molecules18055498
• 作为产物：
  描述：

  吲哚-3-乙醛酰氯 在 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 2.0h， 生成 methyl 2-(1-butyl-1H-indol-3-yl)-2-oxoacetate
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 3-Benzisoxazolyl-4-indolylmaleimides as Potent, Selective Inhibitors of Glycogen Synthase Kinase-3β

  摘要：

  一系列新型的3-苯并异恶唑基-4-吲哚基-马来酰亚胺被合成并评估了它们对GSK-3β的抑制活性。大多数化合物表现出对GSK-3β的高抑制效力。其中，化合物7j以其0.73 nM的IC50值成为最有潜力的GSK-3β抑制剂。初步的结构-活性关系研究表明，吲哚环上及N1位上的不同取代基对GSK-3β抑制活性有不同程度的影响。化合物7c、7f、7j–l以及7o–q能在基于细胞的功能性检测中明显降低由Aβ诱导的Tau蛋白质过度磷酸化，这是通过抑制GSK-3β实现的。

  DOI：

  10.3390/molecules18055498

文献信息

• Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents
  作者：Qing Ye、Weili Mao、Yubo Zhou、Lei Xu、Qiu Li、Yuanxue Gao、Jing Wang、Chenhui Li、Yazhou Xu、Yuan Xu、Hong Liao、Luyong Zhang、Jianrong Gao、Jia Li、Tao Pang

  DOI：10.1016/j.bmc.2014.12.026

  日期：2015.3

  A series of novel 3-([1,2,4] triazolo[4,3-a] pyridin-3-yl)-4-(indol-3-yl)-maleimides were designed, prepared and evaluated for their GSK-3 beta inhibitory activities. Most compounds showed high potency to GSK-3 beta inhibition with high selectivity. Among them, compounds 7c, 7f, 7h, 7l and 7m significantly reduced GSK-3 beta substrate Tau phosphorylation at Ser396 in primary neurons, showing the inhibition of cellular GSK-3 beta. In the in vitro neuronal injury models, compounds 7c, 7f, 7h, 7l and 7m prevented neuronal death against glutamate, oxygen-glucose deprivation and nutrient serum deprivation which are associated with cerebral ischemic stroke. In the in vivo cerebral ischemia animal model, compound 7f reduced infarct size by 15% and improved the neurological deficit following focal cerebral ischemia. These findings may provide new insights into the development of novel GSK-3b inhibitors with potential neuroprotective activity. (C) 2015 Published by Elsevier Ltd.
• Synthesis and Evaluation of 3-(furo[2,3<i>-b</i>]pyridin-3-yl)-4-(1H-indol-3-yl)-maleimides as Novel GSK-3<i>β</i>Inhibitors and Anti-Ischemic Agents
  作者：Qing Ye、Qiu Li、Yubo Zhou、Lei Xu、Weili Mao、Yuanxue Gao、Chenhui Li、Yuan Xu、Yazhou Xu、Hong Liao、Luyong Zhang、Jianrong Gao、Jia Li、Tao Pang

  DOI：10.1111/cbdd.12546

  日期：2015.10

  A series of novel 3‐(furo[2,3‐b]pyridin‐3‐yl)‐4‐(1H‐indol‐3‐yl)‐maleimides were designed, synthesized, and biologically evaluated for their GSK‐3β inhibitory activities. Most compounds showed favorable inhibitory activities against GSK‐3β protein. Among them, compounds 5n, 5o, and 5p significantly reduced GSK‐3β substrate tau phosphorylation at Ser396 in primary neurons, indicating inhibition of cellular GSK‐3β activity. In the in vitro neuronal injury models, compounds 5n, 5o, and 5p prevented neuronal death against glutamate, oxygen–glucose deprivation, and nutrient serum deprivation which are closely associated with cerebral ischemic stroke. In the in vivo cerebral ischemia animal model, compound 5o reduced infarct size by 10% and improved the neurological deficit. The results may provide new insights into the development of novel GSK‐3β inhibitors with potential neuroprotective activity against brain ischemic stroke.